---
layout: minimal-medicine
nav_exclude: true
title: Denosumab
---

# Denosumab

**Generic Name:** Denosumab

**Usage:**

Denosumab is primarily used to treat:

* **Osteoporosis:**  It increases bone mineral density and reduces the risk of fractures in postmenopausal women and men at high risk of fracture.
* **Bone metastases associated with solid tumors (e.g., breast cancer, prostate cancer, lung cancer, multiple myeloma):** It helps reduce bone pain and the risk of skeletal-related events (SREs) like fractures, spinal cord compression, and radiation therapy or surgery to the bones.
* **Giant cell tumor of bone (GCTB):**  A rare bone tumor. It helps shrink the tumor and reduces the need for surgery.
* **Hypercalcemia of malignancy:** High blood calcium levels caused by cancer.


**Side Effects:**

Common side effects include:

* **Infections:**  Increased risk of infections, including skin infections, pneumonia, and urinary tract infections. This is a significant concern.
* **Hypocalcemia (low blood calcium):** Especially in patients with pre-existing low calcium levels.  Symptoms can include muscle cramps, spasms, tingling, and numbness.
* **Musculoskeletal pain:**  Pain in muscles and bones.
* **Nausea, vomiting, constipation:** Gastrointestinal issues.
* **Dermatitis (skin rash):**
* **Osteonecrosis of the jaw (ONJ):** A serious complication where bone in the jaw dies.  Risk is increased in patients undergoing dental procedures.
* **Atypical femoral fractures:**  Unusual fractures in the thigh bone.
* **Hypersensitivity reactions:** Allergic reactions.


**Rare but serious side effects:**

* **Serious infections:** Including sepsis.
* **Hypocalcemic seizures:**
* **Renal impairment (kidney problems):**


**How it Works:**

Denosumab is a monoclonal antibody that works by targeting and inhibiting RANKL (receptor activator of nuclear factor kappa-B ligand).  RANKL is a protein crucial in the process of bone resorption (bone breakdown). By blocking RANKL, denosumab reduces the activity of osteoclasts, the cells responsible for breaking down bone tissue. This leads to increased bone mineral density and reduced risk of fractures.


**FAQs:**

* **How is denosumab administered?** It is administered via subcutaneous injection (under the skin).
* **How often is denosumab given?** The frequency of administration depends on the condition being treated and is determined by a physician. It's typically every 6 months for osteoporosis.
* **Can I take denosumab with other medications?**  It's crucial to inform your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements, as interactions are possible.
* **What should I do if I miss a dose?**  Contact your doctor immediately to determine the best course of action.
* **What are the long-term effects of denosumab?** Long-term effects are still being studied, but potential concerns include increased risk of infections and bone fractures after treatment is stopped.
* **Is denosumab right for me?**  This is a decision that should be made in consultation with your doctor.  They will consider your individual medical history and risk factors.


**Disclaimer:** This information is for general knowledge and does not constitute medical advice.  Always consult with your doctor or other qualified healthcare professional before starting any new medication or treatment.  They can assess your individual needs and determine if denosumab is appropriate for you.


**Note:** This information is AI-generated or crowd-sourced and may not be accurate. Please consult a medical professional for verified advice.